



## ESOCAP RECEIVES ORPHAN DRUG DESIGNATION FROM THE UNITED STATES FOOD & DRUG ADMINISTRATION FOR ESO-101

*Basel, Switzerland, July 23, 2019*

EsoCap AG has received Orphan Drug Designation from the United States Food & Drug Administration (FDA) for use of ESO-101 in the treatment of EoE (eosinophilic esophagitis).

“We are pleased that the FDA has recognized ESO-101’s potential to offer a significant therapeutic benefit for patients suffering from EoE”, said Isabelle Racamier, EsoCap AG CEO, “We believe that EsoCap’s highly promising and innovative technology will represent a major advance for this rare condition”.

The FDA Office of Orphan Products Development grants orphan status to drugs that are intended for safe and effective treatment, diagnosis, or prevention of rare diseases or disorders that affect fewer than 200,000 people in the United States. Orphan Drug Designation provides a sponsor with certain benefits and incentives, including a period of marketing exclusivity when regulatory approval is obtained for the designated indication.

### **About EoE**

EoE is a chronic, local immune-mediated esophageal disease, characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation (A. J. Lucendo et al., 2017; Simon et al., 2017). EoE is the leading cause of dysphagia and food impaction in patients affected by EoE.

### **About EsoCap**

EsoCap AG is a privately funded company based in Basel, Switzerland.

EsoCap’s vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through development of a unique topical drug delivery platform.

Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve, due to ultra-short transit times, with less than two seconds from mouth to stomach.

EsoCap owns a unique drug delivery platform, allowing topical application of drug substances for local treatment of diseases of the upper gastrointestinal tract, enabling esophagus mucosa contact times never seen before.

For more information, please visit [www.esocapbiotech.com](http://www.esocapbiotech.com).

### **Contact:**

Isabelle Racamier, CEO

EsoCap AG  
Malzgasse 9  
4052 Basel  
Switzerland

[isabelle.racamier@esocapbiotech.com](mailto:isabelle.racamier@esocapbiotech.com)